TRANSFORM
the experience of chemotherapy and radiotherapy for caner patients
Chemotherapy Induced Myelosuppression
Chemotherapy is unselective and it can not distinguish between cancer cells and healthy cells. Its many side effects can turn life upside down. Myelosuppression is the most common dose-limiting side effect and may cause anemia, neutropenia and thrombocytopenia. Patients will experience many health problems including fatigue, weakness, life threatening infections, and excessive bleeding complications, to name a few. These side effects cause poor quality of life, requiring multiple supportive cares to manage the myelosuppression symptoms. In addition, patients end up with incomplete chemo treatments. Overall, Myelosuppression Severely Limit the Benefits of chemotherapy and cause huge health and financial burdens.
MyeloShield Therapeutics
MyeloShield is a transformative solution to prevent myelosuppression. Patients will be given MyeloShield before they receive their normal chemodrugs. Now, the healthy cells in the body is protected to prevent myelosuppression. This is a paradigm shift in the clinical management of chemotherapy induced myelosuppression, it is a shift from current largely reactive approach to a proactive approach.
MyeloShield Makes Chemotherapy Safer and More Effective to Save More Lives.
MyeloShield is based on our proprietary, patented peptide drug conjugate (PDC) technology. Our PDC is a novel bone marrow drug delivery system; MyeloShield delivers a cytoprotective molecule to bone marrow protecting hematopoietic stem and progenitor cells. MyeloShield enables selective chemoprotection of healthy cells.